Ocrelizumab (OCR) is an anti-CD20 monoclonal antibody approved for the treatment of relapsing-remitting and primary-progressive multiple sclerosis (MS). We aimed to evaluate the effectiveness of an individualized OCR extended interval dosing (EID), after switching from standard interval dosing (SID).
Methods:
This was a retrospective, observational, single-centre study including MS patients regularly followed at the Neurocenter of Southern Switzerland. After a cumulative OCR dose ⩾1200 mg, stable patients were switched to EID (OCR infusions following CD19+ 27+ memory B cell repopulation).
Results:
A total of 128 patients were included in the study, and 113 (88.3%) were switched to EID with a median interval of 9.9 (8.8–11.8) months between infusions. No clinical relapses occurred; 2 (1.8%) patients experienced disability worsening. Three (2.7%) and 2 (1.8%) patients experienced new T2 brain and spinal lesions, respectively. There was a mild decrease in IgG and IgM concentrations during both SID and EID OCR regimens (β = −0.23, p = 0.001 and β = −0.07, p < 0.001, respectively).
Conclusion:
Switch to personalized dosing of OCR based on CD19+ 27+ memory B cell repopulation led to a great extension of the interval between infusions, with maintained clinical and radiological efficacy. Given the potential advantages in terms of safety and health costs, EID OCR regimens should be further investigated.
SyedYY. Ocrelizumab: A review in multiple sclerosis. CNS Drugs2018; 32(9): 883–890.
2.
HauserSL. The Charcot Lecture| Beating MS: A story of B cells, with twists and turns. Mult Scler2015; 21(1): 8–21.
3.
HauserSLBar-OrAComiG, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376(3): 221–234.
4.
MontalbanXHauserSLKapposL, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med2017; 376(3): 209–220.
5.
HabekMPiskačDGabelićT, et al. Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab. Mult Scler Relat Disord2022; 62: 103798.
6.
ChisariCGSgarlataEArenaS, et al. Rituximab for the treatment of multiple sclerosis: A review. J Neurol2022; 269(1): 159–183.
7.
BakerDPryceGJamesLK, et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord2020; 44: 102279.
8.
BarunBGabelićTAdamecI, et al. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. Mult Scler Relat Disord2021; 48: 102704.
9.
EllrichmannGBolzJPeschkeM, et al. Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol2019; 266(1): 57–67.
10.
BakerDMartaMPryceG, et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine2017; 16: 41–50.
11.
DiSanoKDGilliFPachnerAR. Memory B cells in multiple sclerosis: Emerging players in disease pathogenesis. Front Immunol2021; 12: 676686.
12.
BakerDHerrodSSAlvarez-GonzalezC, et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm2017; 4(4): e360.
13.
MaaroufARicoABoutiereC, et al. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?Neurol Neuroimmunol Neuroinflamm2020; 7(5): e825.
14.
CucuzzaMEPavonePD’AmbraA, et al. Autoimmune encephalitis and CSF anti-AMPA GluR3 antibodies in childhood: A case report and literature review. Neurol Sci2022; 43: 5237–5241.
15.
KimSHKimWLiXF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol2011; 68(11): 1412–1420.
16.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
17.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology1983; 33(11): 1444–1452.
18.
PalanichamyAJahnSNicklesD, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol2014; 193(2): 580–586.
19.
AbdelRazekMACasasolaMMollashahiR, et al. Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease. Mult Scler Relat Disord2022; 59: 103505.
20.
RolfesLPawlitzkiMPfeufferS, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm2021; 8(5): e1035.
21.
ZanghìAAvolioCSignorielloE, et al. Is it time for ocrelizumab extended interval dosing in relapsing remitting MS? Evidence from an Italian multicenter experience during the COVID-19 pandemic. Neurotherapeutics2022; 19(5): 1535–1545.
22.
GuerrieriSBuccaCNozzolilloA, et al. Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: A real-world experience. Eur J Neurol2023; 30(9): 2859–2864.
23.
SchuckmannASteffenFZippF, et al. Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis. Med2023; 4(6): 361.e3–372.e3.
24.
Van LieropZYTooropAAVan BallegoijWJ, et al. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult Scler2022; 28(7): 1121–1125.
25.
BakerDPryceGJamesLK, et al. Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. Eur J Neurol2020; 27: 221–228.
26.
JelcicIAl NimerFWangJ, et al. Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell2018; 175(1): 85.e23–100.e23.
27.
Asplund HögelinKRuffinNPinE, et al. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients. Eur J Neurol2022; 29(11): 3317–3328.
28.
EislerJJDisantoGSaccoR, et al. Influence of disease modifying treatment, severe acute respiratory syndrome coronavirus 2 variants and vaccination on coronavirus disease 2019 risk and outcome in multiple sclerosis and neuromyelitis optica. J Clin Med2023; 12(17): 5551.
ZuroffLRezkAShinodaK, et al. Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age. EBioMedicine2022; 82: 104179.
31.
PukoliDVécseiL. Smouldering lesion in MS: Microglia, lymphocytes and pathobiochemical mechanisms. Int J Mol Sci2023; 24: 12631.
32.
GiovannoniGPopescuVWuerfelJ, et al. Smouldering multiple sclerosis: The ‘real MS’. Ther Adv Neurol Disord. Epub ahead of print 25 January 2022. DOI: 10.1177/17562864211066751.
33.
HauserSLBar-OrAWeberMS, et al. Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2023; 10(2): e200094.
34.
DisantoGBarroCBenkertP, et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol2017; 81(6): 857–870.
35.
AbdelhakAFoschiMAbu-RumeilehS, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol2022; 18: 158–172.
